MG 靶向生物制剂的适用人群和治疗时机是什么

参考文献

[1] Iorio R. Myasthenia gravis: the changing treatment landscape in the eraof molecular therapies[J]. Nat Rev Neurol. 2024 Feb;20(2):84-98.

[2] Gilhus NE, Andersen H, Andersen LK,et al. Generalized myastheniagravis with acetylcholine receptor antibodies: A guidance for treatment[J].Eur J Neurol. 2024 May;31(5):e16229.

[3] De Bleecker JL, Remiche G, Alonso-Jiménez A, et al. Recommendationsfor the management of myasthenia gravis in Belgium[J]. Acta Neurol Belg.2024 Aug;124(4):1371-1383.

[4] 中国罕见病联盟神经罕见病专业委员会,中国罕见病联盟重症肌无力协作组,中华医学会神经病学分会神经肌肉病学组,中国难治性全身型重症肌无力诊断和治疗专家共识（2024 版）[J].中华神经科杂志,2024，57(08) : 840-847.